.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The INCREASE trial evaluated inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease. The randomized, placebo-controlled study demonstrated an improvement in exercise capacity measured by the six-minute walk distance and reduced the risk of clinical worsening compared with placebo. The findings are important because pulmonary hypertension in ILD can add a major burden of symptoms and functional limitation, yet treatment options historically have been limited. The study supports the idea that pulmonary vascular disease should be actively considered when symptoms or functional decline appear disproportionate to the underlying parenchymal lung disease. This is closely aligned with the NAPCON session on screening for pulmonary hypertension in progressive ILD. For HCPs, the message is to recognize when pulmonary vascular evaluation may add diagnostic and therapeutic value rather than assuming every decline is caused by worsening fibrosis alone. The treatment studied here is specific to pulmonary hypertension associated with ILD and should not be generalized to all forms of pulmonary hypertension. The paper is especially useful for multidisciplinary care involving ILD specialists, pulmonary hypertension teams and rehabilitation services.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The INCREASE trial evaluated inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease. The randomized, placebo-controlled study demonstrated an improvement in exercise capacity measured by the six-minute walk distance and reduced the risk of clinical worsening compared with placebo. The findings are important because pulmonary hypertension in ILD can add a major burden of symptoms and functional limitation, yet treatment options historically have been limited. The study supports the idea that pulmonary vascular disease should be actively considered when symptoms or functional decline appear disproportionate to the underlying parenchymal lung disease. This is closely aligned with the NAPCON session on screening for pulmonary hypertension in progressive ILD. For HCPs, the message is to recognize when pulmonary vascular evaluation may add diagnostic and therapeutic value rather than assuming every decline is caused by worsening fibrosis alone. The treatment studied here is specific to pulmonary hypertension associated with ILD and should not be generalized to all forms of pulmonary hypertension. The paper is especially useful for multidisciplinary care involving ILD specialists, pulmonary hypertension teams and rehabilitation services.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
